Norgine sells certain rights for Camcolit and Somnite to Essential Pharma

Netherlands-headquartered independent drugmaker Norgine has agreed to sell all rights in the UK for Somnite (nitrazepam mixture oral suspension BP) and the commercial rights in the UK and Ireland for Camcolit (lithium carbonate) to Essential Pharma.

Somnite is a prescription only medicine and is used to treat insomnia and Camcolit is a prescription only medicine for the treatment of mania, manic depressive illnesses and the treatment of aggressive or self-mutilating behavior.

Under the terms of the agreement, financial details f which were not disclosed, Essential Pharmaceuticals will become the Market Authorization holder for Somnite in the UK and Camcolit in the UK and Ireland. Norgine will continue to commercialize Camcolit in countries outside the UK and Ireland but will no longer commercialize Somnite. The financial terms of the divestment are not being disclosed.